RecruitingObesityOverweightCigarette Smoking
Semaglutide for Post-Smoking Cessation Weight Management
Eligible age
18–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
Sponsor: The University of Texas Health Science Center, Houston
You may qualify if…
- ✓ Ability to provide informed consent before any study-related activity, willing to comply with al study procedures, and be available for the duration of the study.
- ✓ Body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension (unless meets medical exclusion criterion 7), cardiovascular disease (unless meets medical exclusion criterion 6), dyslipidemia, or obstructive sleep apnea
- ✓ Have been smoking ≥5 cigarettes per day for at least 1 year (prior to screening) and provide positive cotinine test.
- ✓ Desire to quit smoking (defined as "intend to quit within one month")
- ✓ Agree (if the participant is female and of child-bearing potential) to use effective contraceptive methods, unless the participant's male partner(s) is surgically sterile (underwent vasectomy).
- ✓ Women of child-bearing potential must provide negative urine pregnancy tests prior to randomization.
- ✓ Normal cognitive restraint (assessed as cognitive restraint score of \<4 from the Three Factor Eating Habits Questionnaire)
- ✓ Have a medical history and a brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the Study Physician and the Principal Investigator
You may not qualify if…
- ✕ Medical Exclusions
- ✕ Personal or first-degree relative(s) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
- ✕ Acute pancreatitis within the past 6 months prior to screening.
- ✕ History or presence of chronic pancreatitis.
- ✕ Type 1 or type 2 Diabetes Mellitus (previously diagnosed or indicated by HbA1C ≥48 mmol/mol (6.5%) as measured by central laboratory at screening).
- ✕ End stage renal disease (ESRD, previously diagnosed or indicated by estimated glomerular filtration rate (eGFR) value of eGFR \< 15 ml/min/1.73 m2 as measured by central laboratory at screening).
- ✕ Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischemic attack within the past 60 days prior to screening.
- ✕ Systolic blood pressure (SBP) \>159 mmHg and/or diastolic blood pressure (DBP) \>99 mmHg)
Where it's recruiting
Texas
Austin · Houston
Source: ClinicalTrials.gov · NCT06173778 · last updated 2026-02-11